Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06958796 · ClinicalTrials.gov registry record · Phase 4
Strategic Help With Immunoglobulin to Enhance Protect Against Late Disease (CMV)
A Phase 4 study of Kidney Transplant; Complications and Liver Transplant, Complications, sponsored by Camille N. Kotton, MD.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 80
- Enrollment target
- 2
- Study locations
NCT06958796 is a Phase 4 study of Kidney Transplant; Complications and Liver Transplant, Complications that is actively recruiting participants, run by Camille N. Kotton, MD. The registered enrollment target is 80 participants, below the 118-participant average among 19 other Kidney Transplant; Complications trials with a reported enrollment target (32% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT06958796, a Phase 4 study of Kidney Transplant; Complications and Liver Transplant, Complications, is actively recruiting participants, sponsored by Camille N. Kotton, MD.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 80 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study is being done to find out if administering CytoGam® after the end of standardly prescribed preventive antiviral treatment can help transplant recipients with a high risk for developing late CMV disease after a liver and/or kidney transplant.
Conditions Studied
Interventions
- DRUG Cytomegalovirus Immune Globulin Intravenous (Human) monthly for three months
Study Locations (2)
Massachusetts
- Massachusetts General Hospital - Boston
Texas
- University of Texas Southwestern - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2025-11-27 |
| Est. Completion | 2028-05-31 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06958796
The ClinicalTrials.gov registry entry for NCT06958796 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 118-participant average among 19 other Kidney Transplant; Complications trials with a reported enrollment target (32% lower). The listed sponsor is Camille N. Kotton, MD, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Kidney Transplant; Complications appearing as the primary indexed condition, and to 1 intervention - of which Cytomegalovirus Immune Globulin Intravenous (Human) monthly for three months is the first listed.
NCT06958796 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Massachusetts, Texas.
Frequently Asked Questions
What is clinical trial NCT06958796 about?
NCT06958796 is a clinical study titled "Strategic Help With Immunoglobulin to Enhance Protect Against Late Disease (CMV)". This study is being done to find out if administering CytoGam® after the end of standardly prescribed preventive antiviral treatment can help transplant recipients with a high risk for developing late CMV disease after a liver and/or kidney transplant.
What is the current status of trial NCT06958796?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 80 participants. The study started on 2025-11-27. Estimated completion is 2028-05-31.
What conditions does trial NCT06958796 study?
This clinical trial studies the following conditions: Kidney Transplant; Complications, Liver Transplant, Complications, Cytomegalovirus, Organ Transplant, Simultaneous Liver-Kidney Transplantation; Complications.
What interventions are being tested in trial NCT06958796?
The interventions under investigation include: Cytomegalovirus Immune Globulin Intravenous (Human) monthly for three months (DRUG).
Who is sponsoring clinical trial NCT06958796?
This trial is sponsored by Camille N. Kotton, MD, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06958796 being conducted?
This trial has 2 study locations across Massachusetts, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Kidney Transplant; Complications
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Efficacy and Mechanisms of Dapagliflozin in Promoting Kidney Function and Cardiovascular Health in Kidney Transplant Recipients
RECRUITING · Phase 4
-
Effect of Alkali Therapy on Vascular and Graft Function in Kidney Transplant Recipients
RECRUITING · Phase 4
-
Pulse Wave Velocity, Tacrolimus Time in Therapeutic Range and CV in African American Kidney Transplants
ACTIVE NOT RECRUITING · Phase 4
-
A Study to Evaluate Preemptive Therapy in Hepatitis C (HCV) Organ Transplant Recipients
ACTIVE NOT RECRUITING · Phase 4
-
Sugammadex Versus Neostigmine for Reversal of Neuromuscular Blockade at the End of Kidney Transplantation Surgery
COMPLETED · Phase 4
-
Immune Registry for BK in Kidney Transplant Recipients
RECRUITING
Explore more on PlainTrial
Kidney Transplant; Complications
All registered trials for this condition
Liver Transplant, Complications
All registered trials for this condition
Massachusetts
All trials with a study site in Massachusetts
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.